ABL Diagnostics Submits Bid to Acquire IntegraGen Under Judicial Restructuring
The molecular diagnostics company has submitted an offer targeting the activities and assets of IntegraGen, a genomic analysis specialist placed under judicial restructuring proceedings.
The transaction remains subject to the decision of the Évry Commercial Court, with no certainty at this stage regarding its outcome.
ABL Diagnostics announced on September 11, 2026 that it has submitted an offer intended to acquire the activities and assets of IntegraGen, a company specializing in genomic analysis of nucleic acids, particularly in oncology and rare genetic diseases.
IntegraGen is currently subject to judicial restructuring proceedings opened before the Évry Commercial Court. The offer was submitted pursuant to Article L.642-1 of the French Commercial Code.
According to the group, this initiative is part of its growth strategy and the examination of external growth opportunities complementary to its current portfolio.
ABL Diagnostics specifies that the envisaged acquisition remains subject to the decision of the Évry Commercial Court. At this stage, the company indicates that there is no assurance that it will be selected as the preferred bidder.
The Outcome Subject to the Court's Decision
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
The offer constitutes a candidacy for acquisition within the framework of a judicial procedure, the outcome of which depends on the Évry Commercial Court. ABL Diagnostics has indicated that it will keep the market informed of any material developments relating to this matter, in compliance with applicable regulatory requirements.
The press release specifies that this announcement contains inside information within the meaning of Article 7 of the European market abuse regulation, the publication of which occurs in accordance with Article 17 of that regulation.
The company recalls that forward-looking statements contained in the press release inherently involve risks and uncertainties, linked in particular to the outcome of the judicial procedure and to third-party approval.
IntegraGen, A Specialist in Genomic Analysis
IntegraGen is presented as a company specializing in genomic analysis of nucleic acids, with positioning in oncology and rare genetic diseases.
ABL Diagnostics, headquartered in Woippy, is listed on Compartment B of the regulated market of Euronext in Paris. The group develops molecular biology tests, software and services intended for biology laboratories and clinical research.
Following the acquisition of Texcell's activities, the company has expanded its operations in life sciences, with services dedicated to virology, biosafety testing and support for biopharmaceutical development.
SectorDiagnostic et services de laboratoire›Diagnostic / labos d'analyse
Free · every morning · before 9am
Never miss a move on your stocks
The trend behind the prices · Euronext
✓ You're in! Check your spam folder.
An error occurred.
Context
Period
Period: S1 2026
Key reported figures
Revenue: 5,4 millions d'euros
Quarterly revenue: 5,4 millions d'euros
Revenue growth: 90,1 %
EBITDA: 1,3 millions d'euros
EBITDA margin: 24,3 %
Net income: 1,3 millions d'euros
1 millions d'euros
Guidance from the release
The achievement of this objective remains dependent on: the timing of orders and deliveries; the ramp-up of the UltraGene range; the development of HIV activities; the contribution of Vela Diagnostics and CDL Pharma; supply conditions; regulatory deadlines
Risks mentioned
Timing of orders and deliveries remains uncertain and critical to achieving 2026 targets
Ramp-up execution of UltraGene range and HIV activities could face delays or operational challenges
Integration of Texcell France operations needs to successfully combine cultures and operations while maintaining financial discipline
Opportunities identified
Ramp-up of the UltraGene range (formerly Fast Track Diagnostics) with €1.582 million target for 2026
Expansion of HIV activities with €3.906 million annual target
Integration of Texcell France assets acquired in July 2026, adding 29 new employees and new virology and biosafety testing services
Outlook / guidance
Expected revenue: 13,8 millions d'euros
Management commentary: Sur la base des informations commerciales, opérationnelles et comptables disponibles à la date du présent communiqué, la Société anticipe désormais un chiffre d'affaires compris entre 13,5 M€ et 14,0 M€. Cette fourchette actualise l'objectif de 12,265 M€ publié le 1er juin 2026.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
